Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 03 November, 2005

XTL Biopharm Ltd

XTLbio Present at the Rodman & Renshaw Conf...


  XTL Biopharmaceuticals Ltd. to Present at the Rodman & Renshaw Techvest 7th  
                         Annual Healthcare Conference                          

Rehovot, Israel, 3 November 2005 - XTL Biopharmaceuticals Ltd ('XTLbio') (LSE:
XTL; NASDAQ: XTLB; TASE: XTL) today announced that Ram Waisbourd, Vice
President, Business Development, will present an overview of the Company at the
Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York City.
Mr. Waisbourd's presentation will take place on Monday, 7 November 2005 at 8:10
pm UK time (3:10 pm EST) in the Adams Room at the New York Palace Hotel. A live
audio webcast of Mr. Waisbourd's presentation will be available during the
presentation at http://www.wsw.com/webcast/rrshq7/xtlb/ and will be archived
for a period of 90 days, beginning approximately 3 hours following the
conclusion of the live presentation.

Contacts:

XTLbio

Jonathan Burgin, Chief Financial Officer Tel: +972 8 930 4440

About XTL Biopharmaceuticals Ltd.

Established in 1993, XTL Biopharmaceuticals Ltd. (LSE: XTL; NASDAQ: XTLB; TASE:
XTL) is a biopharmaceutical company engaged in the acquisition, development and
commercialization of pharmaceutical products for the treatment of infectious
diseases, particularly the prevention and treatment of hepatitis B and C.

Cautionary Statement

Some of the statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the US Private Securities Litigation Reform Act of
1995. Among the factors that could cause our actual results to differ
materially, and therefore affect interest by investors in our securities, are
the following: the results of prior trails with XTL-686are not necessarily
indicative of the results we may have in the Phase 1a and 1b trials; and other
risk factors identified from time to time in our reports filed with the various
regulatory bodies. Any forward-looking statements set forth in this press
release speak only as of the date of this press release. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release and prior
releases are available at www.xtlbio.com. The information in our website is not
incorporated by reference into this press release and is included as an
inactive textual reference only.

                                                                               
                                 
                                                                                                                                                                                    

a d v e r t i s e m e n t